New Mexico Cancer Research Alliance
Trial Pipeline
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
NCT06207864
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
NCT03977402
Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NCT03943316
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT06260332
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
NCT03568448
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
NCT02571725
Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography
NCT03979729
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
NCT01821833
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
NCT02470299
Genome Sequencing of Human Cancer Tissues
NCT02105545
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT01670799
Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
NCT01275183
Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung
NCT00832780
Expanded Breast Cancer Registry and Tissue Repository
NCT00322894
Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
NCT00322634
Combination Paclitaxel, Carboplatin and Temozolomide
NCT00249964
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What the Pipeline for New Mexico Cancer Research Alliance Shows
According to the ClinicalTrials.gov registry, New Mexico Cancer Research Alliance is linked to 43 US clinical trials across every stage of research activity. Of those, 30 studies are currently recruiting — about 70% of the sponsor's indexed portfolio — and 10 are already marked complete, representing roughly 23% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for New Mexico Cancer Research Alliance reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 4 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for New Mexico Cancer Research Alliance is Ovarian Cancer with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.